首页> 美国卫生研究院文献>The Journal of Biological Chemistry >Inhibition of the First Step in Synthesis of the Mycobacterial Cell Wall Core Catalyzed by the GlcNAc-1-phosphate Transferase WecA by the Novel Caprazamycin Derivative CPZEN-45
【2h】

Inhibition of the First Step in Synthesis of the Mycobacterial Cell Wall Core Catalyzed by the GlcNAc-1-phosphate Transferase WecA by the Novel Caprazamycin Derivative CPZEN-45

机译:新型辣椒碱衍生物CPZEN-45抑制由GlcNAc-1-磷酸转移酶WecA催化的分枝杆菌细胞壁核心合成的第一步

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Because tuberculosis is one of the most prevalent and serious infections, countermeasures against it are urgently required. We isolated the antitubercular agents caprazamycins from the culture of an actinomycete strain and created CPZEN-45 as the most promising derivative of the caprazamycins. Herein, we describe the mode of action of CPZEN-45 first against Bacillus subtilis. Unlike the caprazamycins, CPZEN-45 strongly inhibited incorporation of radiolabeled glycerol into growing cultures and showed antibacterial activity against caprazamycin-resistant strains, including a strain overexpressing translocase-I (MraY, involved in the biosynthesis of peptidoglycan), the target of the caprazamycins. By contrast, CPZEN-45 was not effective against a strain overexpressing undecaprenyl-phosphate–GlcNAc-1-phosphate transferase (TagO, involved in the biosynthesis of teichoic acid), and a mutation was found in the tagO gene of the spontaneous CPZEN-45-resistant strain. This suggested that the primary target of CPZEN-45 in B. subtilis is TagO, which is a different target from that of the parent caprazamycins. This suggestion was confirmed by evaluation of the activities of these enzymes. Finally, we showed that CPZEN-45 was effective against WecA (Rv1302, also called Rfe) of Mycobacterium tuberculosis, the ortholog of TagO and involved in the biosynthesis of the mycolylarabinogalactan of the cell wall of M. tuberculosis. The outlook for WecA as a promising target for the development of antituberculous drugs as a countermeasure of drug resistant tuberculosis is discussed.
机译:由于结核病是最普遍和最严重的感染之一,因此迫切需要采取对策。我们从放线菌菌株的培养物中分离出抗结核药卡普沙霉素,并创建了CPZEN-45作为卡普沙霉素最有希望的衍生物。在此,我们首先描述CPZEN-45对枯草芽孢杆菌的作用方式。与卡普沙霉素不同的是,CPZEN-45强烈抑制放射性标记的甘油掺入生长的培养物中,并显示出对耐卡普沙霉素的菌株的抗菌活性,其中包括过度表达Translocase-I的菌株(MraY,参与了肽聚糖的生物合成),这是卡普沙霉素的靶标。相比之下,CPZEN-45不能有效对抗过表达十一碳烯酸-磷酸-GlcNAc-1-磷酸转移酶(TagO,参与磷壁酸的生物合成)的菌株,并且在自发CPZEN-45的tagO基因中发现了一个突变抗性菌株。这表明枯草芽孢杆菌中CPZEN-45的主要靶标是TagO,它与亲本辣椒素的靶标不同。通过评价这些酶的活性证实了这一建议。最后,我们证明CPZEN-45对结核分枝杆菌的WecA(Rv1302,也称为Rfe)有效,它是TagO的直系同源物,并且参与了结核分枝杆菌细胞壁霉菌半乳糖半乳聚糖的生物合成。讨论了作为抗药性结核病对策的抗结核药物开发的有希望的目标,WecA的前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号